Authors | Country/region | Year of publication | Patients | Follow-up years | LDA | Domains positively associated | Domains not associated | |||||||
Disease activity index | Exclusion of New activity | Major Organ Exclusion | PGA | PDN daily dose | IS use | AM use | Minimal duration | |||||||
Golder et al39 | APLC | 2017 | 1707 | 2.2 | SLEDAI<=4 | Yes | Yes | <=1 | <=7.5 | Allowed | Allowed | NR | SF-36: PCS and MCS Multivariable role physical, bodily pain, general health, social functioning, role emotional, vitality, mental health univariable | SF-36: Physical function univariable |
Poomsalood et al24 | Thailand | 2019 | 237 | Cross-sectional | C-SLEDAI=0 | Allowed | NR | <=5 | Allowed | Allowed | 1 year | 1 year | SLEQOL: Physical, activities, symptom, treatment, mood, self-image, total QoL univariable, LLDAS vs no LDA b: 20.02, p=0.003 Multivariable | |
Ugarte-Gil et al25 | USA | 2019 | 472 | NR | SLAM<=3 | No | No | NR | <=7.5 | Not allowed | Allowed | NR | SF-36: PCS, MCS, physical functioning, role physical, bodily pain, general health, social functioning, role emotional, vitality, mental health | |
Ugarte-Gil et al33 | Peru | 2020 | 243 | 2 | SLEDAI<=4 | No | No | NR | <=7.5 | Allowed | Allowed | at least once | LupusQoL: Physical health, pain, planning, burden to others, emotional health, fatigue | LupusQoL: Intimate relationship, body image |
Louthrenoo et al42 | Thailand | 2020 | 337 | 3.2 | SLEDAI<=4 | Yes | Yes | <=1 | <=7.5 | Allowed | Allowed | NR | Global and all domains of SLEQOL, PCS and MCS SF-36 | |
Kang et al43 | Korea | 2021 | 299 | 4 | C-SLEDAI<=1 | NR | NR | NR | 5 | Allowed | Allowed | NR | PCS and MCS SF-36 | |
Kang et al43 | Korea | 2021 | 299 | 4 | C-SLEDAI<=2 | NR | NR | NR | 0 | Not allowed | Allowed | NR | PCS and MCS SF-36 | |
Kang et al43 | Korea | 2021 | 299 | 4 | SLEDAI<=4 | Yes | Yes | <=1 | <=7.5 | Allowed | Allowed | NR | PCS and MCS SF-36 |
*If an article included more than one definition, a row per definition is included.
AM, antimalarials; HRQoL, health-related quality of life; IS, immunosuppressive drug; LDAS, low disease activity; LLDAS, lupus low disease activity state; ;MCS, Mental Component Summary; NR, not reported; PCS, Physical Component Summary; PDN, prednisone; PGA, Physician Global Assessment; SF-36, 36-Item Short Form Health Survey; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.